Health Canada authorizes functional claims that the probiotic strain DDS-1® “helps alleviate perceived stress and improve irritable bowel syndrome-related quality of life in adolescents and adults”
The ‘gut-brain axis’ has become one of the most cutting-edge areas of research over the past few years, diving into how the fascinating interplay between the brain, gut and microbiome can impact
Statement by CEO Mauricio Graber: “Supported by a strong Q4 performance, Chr. Hansen delivered a solid result for the first twelve months of the extended financial year 2022/23 at the upper end of our guidance with 11% organic revenue growth and an EBIT margin b.s.i. of 26.9%. Throughout the year, we have demonstrated the attractiveness of the markets we serve and the resilience of our business mo
The three HMOs, 2’-FL, LNT and 3-FL, have just been approved by the Chinese Ministry of Agriculture and Rural Affairs, MARA, bringing Chr. Hansen’s HMOs one step closer to final approval for the Chinese market.
Clinical studies in infants, children and adults consistently found that HMO supplementation was safe and well tolerated.
Strong execution by the organization drives solid Q3 results
Statement by CEO Mauricio Graber: “The solid results for Q3 prove the strength of the Chr. Hansen organization which continues to deliver first-class products and innovative solutions to customers around the world, while the process with Novozymes to complete the proposed merger is progressing. Organic growth came in at 9%, driven ma
CEO Lukas Schüpbach has decided to step down from his role at Bacthera, effective August 31st, 2023
Lukas Schüpbach has been with the company since 2020. Lukas has played a critical role in the establishment of Bacthera as a leading global end-to-end contract development and manufacturing service provider in the Live Biotherapeutics industry with clinical and commercial manufacturing sites in S
The 6’-SL HMO from Chr. Hansen is approved for highest use levels in infant formula and follow-on formula in EU
As of June 4, 2023, Chr. Hansen’s HMO 6’-Sialyllactose sodium salt (6’-SL), marketed under the new trademark MyOli™ 6’-SL HMO, is authorized for the EU market and under proprietary protection for five years. This EU authorization includes the highest use level for 6’-SL in infant
A strong first half supporting the full-year outlook
Statement by CEO Mauricio Graber: “The strong results for Q2 confirm the attractiveness of the markets we serve in FC&E and H&N, and the resilience of our customer-focused business model. Organic growth came in higher than expected and reached 11%, driven by both pricing initiatives and volume growth. EBIT b.s.i. increased by 8% des
Final EU authorization of LNT, 3-FL and 3’-SL for safe use in infant formula at the highest dosage levels
Following last May’s positive EFSA assessment of Chr. Hansen’s HMOs lacto-N-tetraose (LNT), 3-fucosyllactose (3-FL) and 3’-sialyllactose (3’-SL), these three important Human Milk Oligosaccharides are now approved in EU for safe use in infant formula and several other categories at the
Solid Q1 supports the outlook for 2022/23
Statement by CEO Mauricio Graber: “The solid results for Q1 show the strength of our business model. Organic growth reached 10%, driven by both volume and pricing initiatives and EBIT b.s.i. increased by 17% supported by the organic growth and exchange rates, leading to an EBIT margin b.s.i. of 24.7%. In light of the Q1 performance we maintain our unde
Experience it firsthand at Food Ingredients Europe, stand 4C180, in Paris, on December 6-8
Ingredient powerhouses CP Kelco and Chr. Hansen are proud to offer customers a collaboration combining their world-leading expertise and solutions to take consumer-friendly, shelf-stable, plant-based yogurt alternatives (“vegurts”) to the next level.
Consumer demand for healthy and more sustainab
Adapting to a changing business environment, outlook for the new financial year is 7-10% organic growth
Statement by CEO Mauricio Graber: “We have delivered a solid financial performance despite a volatile macroeconomic and geopolitical environment. Organic growth reached 9%, EBIT margin b.s.i. 26.8%, and the free cash flow b.a.s.i. ended at EUR 172 million in line with our latest guidance.
Approvals from authorities across the globe bring infant formula closer to breast milk in more countries
New regulatory approvals of Chr. Hansen’s Human Milk Oligosaccharides for infant formula by authorities in Europe, USA, Canada and Israel are paving the way for more market entries and higher usage levels across the globe. The new regulatory wins add to recent approvals in important mark
Solid results in an uncertain macroeconomic environment
Statement by CEO Mauricio Graber: “The execution of our strategy to differentiate as a focused microbial and fermentation technology company continued to deliver solid results with 9% organic growth for the third quarter 2021/22, equal to 13% growth in EUR terms. Our inflation-driven pricing measures started to contribute positively during
Enabling customers to bring more health benefits to bottle-fed babies
Food Standards Australia New Zealand, FSANZ, has approved Chr. Hansen's 2'-FL human milk oligosaccharide for infant formula in Australia and New Zealand. 2'-FL HMO is the most abundant and most studied human oligosaccharide in breast milk, used in infant formula around the world since 2016.
“As one of the leading sup
To help producers meet consumer demands for plant-based products delivering on taste, nutrition and sustainability, Chr. Hansen has developed a range of VEGA™ Boost cultures, our newest addition to the VEGA™ Culture Kit
Chr. Hansen has extended its range of cultures for plant-based dairy alternatives and used them to create a breakthrough, dairy-free fava bean cream cheese that boasts sensa
A peer reviewed article by University of Bologna establishes bacillus-based probiotics as a promising strategy to help tackle the increasing problem of antibiotic resistance, while also reducing the incidence of post-weaning diarrhea in pigs by 30% and mortality in broilers by 6–8%.
A just published review of 131 scientific articles evaluates the effectiveness of Bacillus strains as probiot
Bioscience leader extends its VEGA™ portfolio with a fermentation-enabled solution to help keep plant-based meat alternatives safe and fresh
After launching the VEGA™ Culture Kit for dairy alternatives in 2021, Chr. Hansen is stepping into the meat alternatives arena with the VEGA™ SAFEPRO® range – a new offering designed to keep plant-based alternative proteins safe and fresh for longer. T
Largest data set to date highlights the wide distribution of natural concentrations of human milk oligosaccharides and confirms the safety of intake even at high concentrations
HMOs – important groups of carbohydrates in human breast milk – can, in some cases, be secreted in very high concentrations, and still be safe and well-tolerated by infants.
This is the conclusion of a new study b
Continued solid growth in Food Cultures & Enzymes driven by core segments and accelerated growth in Health & Nutrition; 2021/22 outlook adjusted in response to market volatility and accelerating inflationary pressure
Statement by CEO Mauricio Graber: “In a challenging environment, Chr. Hansen continued its strong growth trajectory, delivering 14% organic growth in the second quarter. Gr
Chr. Hansen is a global, differentiated bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical and agricultural industries. At Chr. Hansen we are uniquely positioned to drive positive change through microbial solutions. We have worked for over 150 years to enable sustainable agriculture, better food and healthier living for more people around the world. Our microbial and fermentation technology platforms, including our broad and relevant collection of around 50,000 microbial strains, have game-changing potential. Matching customer needs and global trends we continue to unlock the power of good bacteria to respond to global challenges such as food waste, global health and the overuse of antibiotics and pesticides. As one of the world’s most sustainable companies, we touch the lives of more than 1 billion people every day. Driven by our legacy of innovation and curiosity to pioneer science, our purpose – To grow a better world. Naturally. – is at the heart of everything we do.
Boege Allé 10-12
DK-2970 Hoersholm
Denmark